Current anti-inflammatory drugs take a systemic approach, affecting ubiquitous molecules such as tubulin or vital immune defence factors like the pro-inflammatory cytokines IL-1β and IL-6. These non-targeted approaches not only raise safety concerns, particularly for vulnerable coronary artery disease patients, but they also do not address the root cause of coronary inflammation.
Orticumab acts directly at the site of coronary artery inflammation, binding to oxLDL and inhibiting local macrophage activation. This targeted approach may not only enhance treatment efficacy and success rates but also may minimize safety risks, making it an appealing therapy for patients in need.
